Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Anisha Gulati

Diagnostic Neuroimaging Stuart, FL Medical Doctor

NPI 1811215205 CMS profile 1293689

5995 Se Community Dr, Stuart, FL 34997

Open in the dashboard

General payments

$415

14 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Anisha Gulati of Stuart, FL is reported in the CMS Open Payments database as having received $415 across 14 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $93 5
2021 General $92 5
2020 General $39 2
2019 General $192 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anisha Gulati
  • Florida median
  • Middle half of Florida
  • National median

In program year 2025, general payments to Anisha Gulati were reported at $0. Among 84,641 Florida profiles paid that year, the median was $195 and the middle half received between $59 and $690.

Show as a table
Year Anisha Gulati Florida median Middle half National median
2019 $192 $197 $63–$719 $163
2020 $39 $126 $38–$436 $114
2021 $92 $151 $45–$537 $132
2022 $93 $175 $53–$607 $149
2023 $0 $183 $57–$637 $160
2024 $0 $185 $56–$647 $164
2025 $0 $195 $59–$690 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $175 1 payment
  2. Otsuka America Pharmaceutical, Inc. $117 6 payments
  3. Janssen Pharmaceuticals, Inc $66 4 payments
  4. Sunovion Pharmaceuticals Inc. $22 1 payment
  5. Teva Pharmaceuticals USA, Inc. $18 1 payment
  6. Neurocrine Biosciences, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $240 13 payments
  2. Consulting Fee $175 1 payment
Products named General payments · program years 2019–2022
  1. ABILIFY MYCITE $175 1 payment
  2. ABILIFY MAINTENA $102 5 payments
  3. REXULTI $93 5 payments
  4. SPRAVATO $66 4 payments
  5. INVEGA SUSTENNA $44 3 payments
  6. INVEGA $44 3 payments
  7. INVEGA TRINZA $44 3 payments
  8. LATUDA $22 1 payment
  9. AUSTEDO $18 1 payment
  10. INGREZZA $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

659

Median for Psychiatry: 574

Drug cost

$12,134

Median for Psychiatry: $27,624

Branded share of claims

23.2%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ramelteon Generic 13 $1,911
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 15 $1,360
Aripiprazole Generic 11 $1,247
Bupropion Xl Bupropion Hcl Brand 54 $1,125
Modafinil Generic 24 $754
Temazepam Generic 21 $593
Quetiapine Fumarate Generic 27 $538
Duloxetine Hcl Generic 26 $405
Methylphenidate Hcl Generic 29 $399
Fluoxetine Hcl Generic 25 $388

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$15,492

Medicare's payments for the services billed

Medicare patients

17

Average age 63

Services billed

207

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 65%
Cancer 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

14 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Neuroimaging in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record